Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

Fact checked by Marley Hall Medically reviewed by Marla Anderson, MD The Food and Drug Administration (FDA) granted priority review for Enhertu (fam-trastuzumab deruxtecan-nxki) in 2024. This drug ...

Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.

AZ has already licensed rights to HER2-targeting drug Enhertu (trastuzumab deruxtecan) – which is already on the market for HER2-positive breast and gastric cancers – as well as ...

Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Additionally, the study did not establish the efficacy of T-Duo in patients previously treated with trastuzumab deruxtecan. This study was supported by Byondis B.V. Co-authors Evelyn van den Tweel ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd ...

Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845 Technology appraisal guidance Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous ...